Umecrine Cognition AB

About

Umecrine Cognition is developing a completely new type of drug for neurological disorders in the brain that can occur as a result of a number of underlying diseases and lead to severely reduced cognition and alertness.

The results from an internationally recognized clinical phase 2 study indicate that the company's most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy.

The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but the mechanism of action is also relevant in a number of other indication areas.

The results from an internationally recognized clinical phase 2 study indicate that the company's most advanced drug candidate, golexanolone, improves brain signaling and cognition and alertness in patients with hepatic encephalopathy.

The continued development of golexanolone is initially focused on patient groups whose symptoms have arisen as a result of chronic liver diseases, but the mechanism of action is also relevant in a number of other indication areas.

Keywords

pbc, biotech, cognitive disorders, drug development, neurological disorders, hepatic encephalopathy, primary biliary cholangitis, fatigue, golexanolone, cognitive function, parkinsons disease, gabaa receptor

Amenities

No amenities listed yet

Upcoming Events

No upcoming events scheduled

Frequently Asked Questions

No reviews yet. Be the first to review!

Social Links

Photo Gallery

No photos available

Contact Information

Business Info

Location

Business Hours

Business hours not available